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Thioredoxin-interacting protein (TXNIP) binds and inhibits the reducing activity of thioredoxin. A new
study (Parikh et al., 2007) implicates this redox rheostat as a negative regulator of peripheral glucose
metabolism in humans. Investigators combined human physiology, genomic screening, and cell-
based genetic studies to highlight TNXIP as a potential culprit in the pathogenesis of type 2 diabetes.Modern technology has created a fa-
vorable climate for the ‘‘perfect meta-
bolic storm’’ that is now raging through
Westernized societies as an epidemic
of obesity and type 2 diabetes (Zimmet
et al., 2001). Topping the list of casual-
ties is glucose homeostasis, a weath-
ered victim of lifestyle habits that
promote overeating and inactivity.
Normal control of blood glucose
depends on exquisite coordination
between the insulin-producing pan-
creatic b cells and insulin-responsive
target tissues such as skeletal muscle,
liver, and fat. In the context of meta-
bolic disease, these target tissues fail
to effectively adjust glucose uptake
and metabolism in response to insulin.
As a result, the b cell must compensate
by amplifying its secretion of the hor-
mone. This insulin-resistant/glucose-
intolerant state is universally present
in patients with type 2 diabetes, a dis-
ease that eventually takes hold when
b cell failure results in sustained hyper-
glycemia.
Relief efforts, in the form of effica-
cious antidiabetic pharmaceuticals,
depend heavily on a deeper under-
standing of the molecular events that
connect energy surplus to glucose
intolerance. To this end, Parikh and
colleagues (2007) have identified thio-
redoxin-interacting protein (TXNIP) as
a potential diabetogenic signal in
human skeletal muscle. TXNIP is
a ubiquitous protein inhibitor of thiore-
doxin, an oxidoreductase that partners
with thioredoxin reductase and thiore-
doxin peroxidase to reduce oxidized
proteins and scavenge free radicals
(Figure 1A). Their investigation fea-
tured a unique translational approach
that combined human physiology412 Cell Metabolism 5, June 2007 ª200studies with genome-wide transcrip-
tomics, genetic association testing,
and cell-based genetic engineering
tools. The initial genomic study in-
volved a screen of 12 healthy subjects
to identify skeletal muscle mRNAs
whose abundance is altered in
response to a euglycemic-hyperinsuli-
nemic clamp. In healthy subjects, ex-
pression levels of TXNIP were potently
suppressed by insulin and negatively
correlated with glucose disposal. By
contrast, these relationships were
lost in diabetic subjects. Using previ-
ously published microarray data, the
investigators found that muscle ex-
pression of TXNIP was consistently
higher in patients with diabetes or
prediabetes as compared to those
with normal glucose tolerance. TXNIP
was not upregulated in muscle of
healthy subjects with a family history
of disease, and the researchers found
no association between diabetes sus-
ceptibility and genetic variation at the
TXNIP locus, suggesting that dysregu-
lation of the gene is an acquired rather
than inherited trait.
Because insulin-mediated regula-
tion of TXNIP was absent in insulin
receptor knockout mice, the investiga-
tors further concluded that suppres-
sion of TXNIP requires intact insulin
signaling. As a complementary ap-
proach, the researchers performed
a series of experiments in terminally
differentiated human skeletal myo-
cytes and adipocytes. In both
systems, administration of insulin sup-
pressed TXNIP mRNA levels, whereas
exposure of cells to high glucose
caused reciprocal upregulation of
the gene. The functional consequence
of these changes was then tested7 Elsevier Inc.by artificial manipulation of TXNIP.
Lentivirus-mediated overexpression
of TXNIP in 3T3-L1 adipocytes
decreased both basal and insulin-
stimulated transport of 2-deoxyglu-
cose, a nonmetabolizable glucose
analog, whereas silencing of the gene
by RNA interference augmented up-
take in both myocytes and adipocytes.
However, the full implications of these
findings cannot yet be fully evaluated
since corresponding effects on glu-
cose metabolism, redox state, oxida-
tive stress, and insulin signaling were
not reported.
The study showed that TXNIP is
reciprocally regulated by insulin and
glucose. To explain this seemingly
counterintuitive finding, the authors
proposed a model in which TXNIP
functions as a homeostatic switch
that integrates glucose sensing and
insulin signaling to control cellular
energy status. For example, insulin-
mediated suppression of TXNIP might
act as a feed-forward signal that en-
hances glucose disposal in the periph-
ery to facilitate post-meal refueling.
Conversely, a surplus of intracellular
glucose activates TXNIP, bringing glu-
cose uptake to halt. This negative
feedback mechanism might serve as
‘‘trip switch’’ that prevents excessive
glucose uptake and metabolism (Fig-
ure 1B). Although the report stopped
short of offering a biological mecha-
nism to explain the relationship
between elevated TXNIP and glucose
intolerance, several intriguing possibil-
ities emerge from previous work.
TXNIP is also known as vitamin
D3-upregulated protein or thioredoxin-
binding protein 2 and inhibits thiore-
doxin function by binding to its
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PreviewsFigure 1. Models of TXNIP Action
(A) Role of TXNIP in the thioredoxin system. Thioredoxin (TXN) reduces oxidized cysteine residues
(protein-S2) on cellular proteins. Reduced TXN (TXN-(SH)2) is regenerated via the action of thio-
redoxin reductase (TXR) at the expenditure of NADPH. When TXN reduces the oxidized form of
thioredoxin peroxidase (TXP), the reduced enzyme (TXP-(SH)2) is available to scavenge reactive
oxygen species (ROS) such as hydrogen peroxide (H2O2) and the superoxide anion (O2
). TXNIP
binds and inhibits the reduced form of TXN, thereby functioning as a rheostat that modulates both
redox status and ROS-mediated signaling to regulate metabolism and other cellular processes.
(Dashed arrows indicate unknown mechanisms.)
(B) Proposed role of TXNIP in type 2 diabetes. Insulin-mediated suppression of skeletal muscle
(skm) TXNIP serves as a feed-forward signal (+) that enhances glucose uptake and facilitates
post-meal refueling. A surplus of intramyocellular (IMC) glucose activates TXNIP, which exerts
negative feedback () to discourage import of additional fuel. The energy burden of overnutrition
and inactivity (blue lines) leads to constitutively high levels of TXNIP in skeletal muscle, which is
further exacerbated by peripheral insulin resistance. This vicious cycle imposes a chronic glucose
load on the pancreas, triggering TXNIP-mediated b cell failure and overt diabetes.redox-active cysteine residues
(Nishiyama et al., 1999). Growing evi-
dence positions the thioredoxin sys-
tem at a nodal point linking pathways
of redox regulation, antioxidant de-
fense, energy metabolism, and cell
growth and survival. TXNIP is elevated
in the vasculature and pancreas of
diabetic animals, suggesting a broadrole in diabetes complications (World
et al., 2006). Notably, TXNIP is also
glucose inducible in pancreatic b cells,
possibly mediating glucotoxicity (Minn
et al., 2005), and overexpression of the
gene sensitizes various cell types to
oxidative stress with concomitant
induction of apoptosis (World et al.,
2006).Cell MetaboliLoss of TXNIP due to a spontaneous
nonsense mutation in HcB-19 mice re-
sults in 3-fold higher insulin levels in
the fasted state, due principally to un-
controlled insulin secretion (Oka et al.,
2006). These mice also display hypo-
glycemia, severe dyslipidemia, hyper-
ketonemia, and liver steatosis. Genetic
ablation of the gene in txnip/ mice
produces a nearly identical phenotype
(Hui et al., 2004). In both mouse
models, the TXNIP null background is
accompanied by a metabolic block
in gluconeogenesis, corresponding in-
creases in the ratio of reduced:oxi-
dized glutathione in liver, and a sus-
pected impairment in TCA cycle
activity. In wild-type mice, fasting
causes a robust induction of TXNIP in
the liver, consistent with TXNIP’s pre-
sumed role in promoting gluconeo-
genesis and suggesting that the gene
can be upregulated by metabolic
cues other than hyperglycemia (Hui
et al., 2004).
The new finding that TXNIP modu-
lates glucose transport in skeletal
muscle fits with the concept that mus-
cle glucose uptake is governed by
cellular energy state; for example,
exercise enhances both basal and
insulin-stimulated glucose uptake.
Signals of energy deficiency such
as accumulation of 50AMP and resul-
tant activation of 50AMP-activated
kinase play an established role in
stimulating muscle glucose uptake in
response to ATP depletion. Con-
versely, mounting clues hint toward
a counteracting ‘‘signal of plenty’’
that puts the brakes on glucose trans-
port when energy reserves are replete
(Muoio and Newgard, 2006). In this
way, sedentary muscles flooded with
fuel in the form of sugar, lipid, and/or
protein are discouraged from import-
ing additional energy sources. Al-
though the molecular nature of this
signal remains a mystery, prominent
candidates include specific lipid-
derived intermediates, which would
play a direct role in blocking insulin
signaling (Morino et al., 2006). Con-
ceivably, however, the message to
abort glucose uptake might instead
(or additionally) stem from changes
in redox potential, as reflected by ad-
justments in NAD(P)H/NAD(P) and as-
sociated regulatory circuits involvingsm 5, June 2007 ª2007 Elsevier Inc. 413
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tively, this scenario could explain glu-
cose intolerance provoked by over-
supply of any metabolic substrate.
Because TXNIP plays a known role
in regulating both redox state and oxi-
dative stress, the new findings also
have relevance for an emergent theory
linking insulin resistance to dysfunc-
tional mitochondria—a potential
source and target of reactive oxygen
species (ROS) (Muoio and Newgard,
2006; Morino et al., 2006). Fluctuations
in redox state impact production of
and defense against ROS, which are
increasingly recognized as bona fide
signaling molecules that can affect
metabolic control. Interestingly, TXNIP
is present in mitochondria and has
been shown to bind the mitochondri-
ally localized isoform of thioredoxin
(Oka et al., 2006), although the biolog-
ical relevance of this interaction
remains unknown. While our under-
standing of how oxidative stress fits
into the etiology of diabetes remains
incomplete, a recent study found414 Cell Metabolism 5, June 2007 ª2007that ROS oppose glucose uptake
and insulin signaling in cultured adipo-
cytes (Houstis et al., 2006). TXNIP-
mediated impairments in glucose
transport might therefore reflect
heightened oxidative stress. This ex-
citing possibility now warrants further
investigation.
Lastly, the report by Parikh et al.
(2007) builds on evidence that pan-
creatic b cells and skeletal myocytes
share common mechanisms of fuel
sensing that ultimately cooperate to
maintain whole-body glucose homeo-
stasis (Muoio and Newgard, 2006).
Whereas the islet responds bymobiliz-
ing insulin-containing vesicles, the
muscle responds by modulating trans-
location of the resident glucose trans-
porters. The recent findings implicate
TXNIP as a diabetogenic culprit that
disrupts both processes. Future
research to gain a more mechanistic
understanding of how TXNIP modu-
lates glucose control might therefore
lead to new therapeutic shelter from
the current stormy climate.Elsevier Inc.REFERENCES
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